Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Cancer Theme, Karolinska University Hospital Solna, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden.
Umeå University, Faculty of Medicine, Department of Radiation Sciences.
Show others and affiliations
2023 (English)In: Cancer, ISSN 0008-543X, E-ISSN 1097-0142, Vol. 129, no 6, p. 946-955Article in journal (Refereed) Published
Abstract [en]

Background: To evaluate the psychosocial consequences of surveillance with whole-body MRI (WB-MRI) in individuals with the heritable TP53-related cancer (hTP53rc) syndrome, also known as the Li-Fraumeni syndrome, with regard to cancer worry, perceived benefits and risks to surveillance and overall health.

Patients and methods: Since 2016, the national Swedish TP53 Study (SWEP53) has offered surveillance with WB-MRI to all individuals with hTP53rc syndrome. Seventy-five individuals have been included in the study. Sixty consecutive participants fulfilled a base-line evaluation as well as an evaluation after 1 year with structured questionnaires including the Cancer Worry Scale (CWS), perceived benefits and risks of surveillance, and the 36-item Short Form Survey (SF-36). Individuals with or without previous personal cancer diagnosis were enrolled and results at baseline and after 1 year of surveillance were compared. For SF-36, a comparison with the normal population was also made.

Results: Participants with previous cancer tend to worry more about cancer, but both individuals with and without cancer had a positive attitude toward surveillance with no differences regarding perceived benefits and barriers to surveillance. Participants with a previous cancer scored significantly lower on some of the SF-36 subscales, but between-group differences were found only for social functioning after 1 year.

Conclusions: Surveillance with WB-MRI is feasible from a psychosocial point of view both among TP53 carriers with as well as without a previous history of cancer and does not increase cancer worry in any of the groups.

Plain language summary:

  • Individuals with heritable TP53-related cancer syndrome (also known as the Li-Fraumeni syndrome) have a high lifetime risk of developing cancer.
  • These TP53 carriers are offered surveillance with whole-body MRI to detect cancer early. There are few reports of the psychosocial impact of surveillance.
  • In this study, we wanted to evaluate cancer worry, benefits and barriers to participation, and perceived overall health.
  • Our study shows no increase in cancer worry after 1 year of surveillance, regardless of previous cancer.
Place, publisher, year, edition, pages
John Wiley & Sons, 2023. Vol. 129, no 6, p. 946-955
Keywords [en]
cancer worry scale, health-related quality-of-life, hereditary cancer, heritable TP53-related cancer syndromes, Li-Fraumeni syndrome, surveillance
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-203569DOI: 10.1002/cncr.34631ISI: 000907544400001PubMedID: 36601958Scopus ID: 2-s2.0-85145678028OAI: oai:DiVA.org:umu-203569DiVA, id: diva2:1728720
Funder
The Cancer Research Funds of Radiumhemmet, 201052Swedish Childhood Cancer Foundation, TJ2018‐0054Swedish Childhood Cancer Foundation, TJ2021‐0125Swedish Cancer Society, CAN 2016/775Available from: 2023-01-19 Created: 2023-01-19 Last updated: 2023-07-14Bibliographically approved

Open Access in DiVA

fulltext(1387 kB)40 downloads
File information
File name FULLTEXT02.pdfFile size 1387 kBChecksum SHA-512
92f35e3ca2fb61ebb380eb311c2eaa363ee77e9545c4244ce4b738b58c4b85a7f1e148f7c32f0745f2b157d3bd04a6590be0d6325fa54b7909dceb61c2a2a788
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Silander, Gustav

Search in DiVA

By author/editor
Silander, Gustav
By organisation
Department of Radiation Sciences
In the same journal
Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 68 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 117 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf